R&D channel feed – Endpoints News

R&D channel feed

#JPM23: Fireside chat with Eisai's Ivan Cheung

3 years ago

TheracosBio aims to challenge Big Pharma blockbusters with newly-approved SGLT2 for diabetes

3 years ago

Pliant posts high-dose data of oral IPF drug with 'quite favorable' safety, outlines trial plans

3 years ago

Israel, EU drug regulators find no link between Pfizer Covid shot and stroke

3 years ago

How small can you ‘omic? New startup wants to profile the tiny space between neurons to study Alzheimer’s

3 years ago

Ipsen's pancreatic cancer drug bests decade-old standard of care

3 years ago

FDA squashes accelerated hopes for Eli Lilly’s Alzheimer’s drug as agency asks for more data

3 years ago

Genentech touts positive Phase III data for Tecentriq/Avastin combo in liver cancer

3 years ago

Sun Pharma buys out Concert, and its alopecia drug, for $576M

3 years ago

Horizon claims mid-stage victory in rare disease, lines up PhIII for new owners at Amgen

3 years ago

Ipsen has go/no-go decision to make after biotech partner's Parkinson's drug flunks PhIIb

3 years ago

Don't pack your sunglasses: No plans to move JP Morgan conference, bank says

3 years ago

Drugmakers seek tweaks to FDA guidance on measuring development in pediatric trials

3 years ago

J&J reports second HIV vaccine regimen failure in 18 months

3 years ago

With CEO search, PhIII study underway, Fulcrum Therapeutics raises $125M from stock offering

3 years ago

Gene therapy side effects prompt search for new delivery methods

3 years ago

Moderna jumps into pivotal pack with promising RSV data as big rivals face off in megablockbuster race

3 years ago

NewAmsterdam notches another win in resurrection of Amgen cardio drug

3 years ago

In ‘clever’ experiment, scientists use gene editing to treat heart disease in mice

3 years ago

Oramed’s insulin pill fails PhIII trial in diabetes, stock craters

3 years ago

Experts talk IRA impacts as CMS announces it will publish first 10 drugs up for negotiation in September

3 years ago

Sanofi extends commitment to $750M biotech startup fund

3 years ago

As Illumina disappoints Wall Street, competitors make their case at JPM

3 years ago

Flame Biosciences searches for future after Novartis flunks on canakinumab

3 years ago

First page Previous page 102 103 104105106 107 108 Next page Last page